Shopping Cart
- Remove All
Your shopping cart is currently empty
R-268712
🥰Excellent
Catalog No. T16708Cas No. 879487-87-3
R-268712 is a specific activin receptor-like kinase 5 (ALK5) inhibitor(IC50 of 2.5 nM). It is also an orally active transforming growth factor-β type I receptor inhibitor.
R-268712
🥰Excellent
Purity: 99.77%
Catalog No. T16708Cas No. 879487-87-3
R-268712 is a specific activin receptor-like kinase 5 (ALK5) inhibitor(IC50 of 2.5 nM). It is also an orally active transforming growth factor-β type I receptor inhibitor.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $39 | In Stock | |
| 5 mg | $89 | In Stock | |
| 10 mg | $139 | In Stock | |
| 25 mg | $278 | In Stock | |
| 50 mg | $419 | In Stock | |
| 100 mg | $596 | In Stock | |
| 200 mg | $847 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $98 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "R-268712"
Hydrochlorothiazide
HCTZ
T144958-93-5
Hydrochlorothiazide (HCTZ) is a Thiazide Diuretic. The physiologic effect of hydrochlorothiazide is by means of Increased Diuresis.
- $48
Size
QTY
Pirfenidone
Cited
S-7701,AMR-69, S-7701, AMR69
T238653179-13-8
Pirfenidone (AMR69) inhibits the production of CCL2 and CCL12 in fibroblasts and also decreases TGF-β2 protein levels. Pirfenidone is an antifibrotic agent that is commonly used in studies related to pulmonary fibrosis and also has anti-inflammatory activity.
- $30
Size
QTY
CitedA 83-01 Cited
ALK5 Inhibitor IV, A8301
T3031909910-43-6
A 83-01 (ALK5 Inhibitor IV) is an inhibitor of the TGF-β type I receptors ALK5, ALK4, and ALK7 (IC50=12/45/7.5 nM). A 83-01 promotes the reprogramming of mouse fibroblasts into iPSCs. A 83-01 can be used in organoid cultures.
- $52
Size
QTY
CitedGalunisertib Cited
LY2157299
T2510700874-72-2
Galunisertib (LY2157299) is a TGF-β receptor type I (TGF-βRI) inhibitor (IC50=56 nM) that is selective. Galunisertib has antitumor activity and can be used in combination with PD-1 inhibitors.
- $40
Size
QTY
CitedAlantolactone Cited
Inula camphor, Helenine, helenin, Eupatal, Alant camphor, (+)-Alantolactone
T2896546-43-0
Alantolactone is a selective inhibitor of STAT3 that induces cancer-associated apoptosis and has antitumor activity.
- $50
Size
QTY
CitedCeritinib Cited
LDK378
T17911032900-25-6
Ceritinib (LDK378) is an ALK tyrosine kinase inhibitor (IC50=200 pM) with selective, ATP-competitive, and oral activity. Ceritinib also inhibits IGF-1R, InsR, and STK22D (IC50=8/7/23 nM). Ceritinib has antitumor activity.
- $45
Size
QTY
CitedChromenone 1
T613011639929-29-5In house
Chromenone 1 is a potent potentiator of osteogenic bone morphogenetic protein (BMP). Chromenone 1 induces a pronounced, kinase-independent, negative TGFβ feedback that enhances nuclear BMP-Smad signaling outputs.
- $70
Size
QTY
Monocrotaline Cited
Crotaline
T2803315-22-0
Monocrotaline (Crotaline) is a pyrrolizidine alkaloid extracted from the seeds of the Crotalaria plant. Monocrotaline has certain cellular activity against HepG2 cells and can induce pulmonary hypertension in rodents.
- $41
Size
QTY
CitedCrizotinib Cited
PF-02341066
T1661877399-52-5
Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinase inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptors.
- $46
Size
QTY
CitedDMH-1 Cited
DMH1
T19421206711-16-1
DMH-1 is a potent and selective Bone Morphogenetic Protein (BMP) inhibitor.
- $53
Size
QTY
CitedBMP signaling agonist sb4 Cited
SB 4
T7799100874-08-6
BMP signaling agonist sb4 (SB 4) is an agonist of benzoxazole bone morphogenetic protein (BMP) signaling (EC50 :74 nM)
- $39
Size
QTY
CitedLY-364947 Cited
LY 364947, HTS466284
T2048396129-53-6
LY-364947 (HTS466284) is a potent ATP-competitive inhibitor of TGFβR-I.
- $59
Size
QTY
CitedSelect Batch
Purity:99.77%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | R-268712 is a specific activin receptor-like kinase 5 (ALK5) inhibitor(IC50 of 2.5 nM). It is also an orally active transforming growth factor-β type I receptor inhibitor. |
| In vitro | R-268712 is a novel and specific inhibitor of activin receptor-like kinase 5 (ALK5), a transforming growth factor β (TGF-β) type I receptor.?Evaluation of in vitro inhibition indicated that R-268712 is a potent and selective inhibitor of ALK5 with an IC50 of 2.5nM, an approximately 5000-fold more selectivity for ALK5 than p38 mitogen-activated protein kinase (MAPK). |
| In vivo | Oral administration of R-268712 at doses of 1, 3 and 10mg/kg also inhibited the development of renal fibrosis in a dose-dependent manner in a unilateral ureteral obstruction (UUO) model.?Additionally, the efficacy of R-268712 in a heminephrectomized anti-Thy1 glomerulonephritis model at doses of 0.3 and 1mg/kg.?R-268712 reduced proteinuria and glomerulosclerosis significantly with improvement of renal function. |
| Molecular Weight | 363.39 |
| Formula | C20H18FN5O |
| Cas No. | 879487-87-3 |
| Smiles | Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1 |
| Relative Density. | 1.34 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 110 mg/mL (302.7 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
UUOTransforming growth factor beta receptorsTransforming growth factor betaThy1 nephritisTGF-β/SmadTGF-β ReceptorTGF-βTGFβTGF-beta/SmadTGFbeta/SmadTGF-betaTGFbetaTGF-b/SmadTGFbSmadrenal fibrosisR-268712R268712R 268712InhibitorinhibitHFL-1glomerulosclerosisglomerulonephritisCluster of differentiation 246CKDCD246Anaplastic lymphoma kinase (ALK)Anaplastic lymphoma kinaseALK tyrosine kinase receptor
Preview
Related Tags: buy R-268712 | purchase R-268712 | R-268712 cost | order R-268712 | R-268712 chemical structure | R-268712 in vivo | R-268712 in vitro | R-268712 formula | R-268712 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.